Li Shi Pharmaceutical Factory (00950.HK): Socazolimab has been approved by the National Medical Products Administration for use in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China.

Zhixin Finance and Economics APP News, Li's Great Pharmaceutical Factory (00950.HK) announced that on July 29, 2025, the company's subsidiary, China Cancer Medical Limited Company's cancer drug Socazolimab, has been approved by the National Medical Products Administration to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China.